Skip to main content


Figure 2 | Journal of Neuroinflammation

Figure 2

From: Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model

Figure 2

Severity of clinical deficits in MOG peptide EAE is diminished by astroglial CXCL10 deletion. (A) Average daily clinical scores and (B) sum of clinical scores of mGFAPcre/CXCLfl/fl (CXCL10 knockout) and CXCLfl/fl littermate (control) mice induced with MOG peptide EAE. Data are shown as means ± SEMs; statistical significance was determined by Wilcoxon-Mann-Whitney test, (n = 14, P = 0.007).

Back to article page